


4CPS-033

M.C. SÁNCHEZ ARGAIZ<sup>1</sup>, B. CANCELA DÍEZ<sup>2</sup>, S. SADYRBAEVA DOLGOVA<sup>2</sup>, R. ÁLVAREZ SÁNCHEZ<sup>3</sup>, M.R. CANTUDO CUENCA<sup>1</sup>.  
<sup>1</sup>SAN AGUSTÍN HOSPITAL, HOSPITAL PHARMACY, LINARES JAÉN, SPAIN, <sup>2</sup>VIRGEN DE LAS NIEVES UNIVERSITY HOSPITAL, HOSPITAL PHARMACY, GRANADA, SPAIN.,  
<sup>3</sup>CAMPUS DE LA SALUD HOSPITAL, HOSPITAL PHARMACY, GRANADA, SPAIN.

ATC code: D05 - Antipsoriatics

The current treatment for psoriasis depends on the severity of the disease




**Apremilast** is an oral option for treating chronic moderate/severe plaque psoriasis in adults whose disease has not responded to other therapies or they are contraindicated/not tolerated.

**Objectives:** To report the hospital cases of moderate/severe plaque psoriasis treated with apremilast, describing patients' profile and analyzing the efficacy and safety of apremilast.

## Methods or Study Design

A retrospective case series. We reviewed the clinical history of the patients with moderate/severe plaque psoriasis treated with apremilast until august 2018.



The adequate response to treatment after 16 weeks:


**PASI90/ PASI75/ PASI50**  
90%, 75% or 50% reduction (improvement) from baseline

We investigated previous treatments since the beginning of the disease, analyzed the efficacy of apremilast collecting the PASI or BSA scores at started, after 16 and 32 weeks and collected the adverse events during the treatment.


## Results:

- ✓ 18 patients
- ✓ 83% men
- ✓ Mean age: 52(±12) years old
- ✓ 3 patients suffered plaque psoriasis and psoriatic arthritis


At **start of apremilast** (3 patients were unvaluable because of the recently started of apremilast):



### severity of the disease at the beginning of the treatment (n=15)



### The efficacy of apremilast (n=15)



### Adverse events during the use of apremilast:

- \* 6 gastrointestinal adverse events
- \* 1 atrial fibrillation
- \* 2 cholesterol increased



<http://www.eahp.eu/24-4CPS-033>

**Discussion/Conclusions:** Almost all patients had received prior systemic therapy with conventional agents and/or biologics. The use of premilast has some advantages included oral administration, well tolerated, and safer profile. It will likely be of value these patients and those who may not be candidates for biologics.